Antibodies
11 September 2007
Merck: Erbitux Phase III Study – FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer11 September 2007
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis8 September 2007
Genmab announces encouraging preclinical data for Ofatumumab8 September 2007
Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeutics8 September 2007
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-4026 September 2007
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor6 September 2007
Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies5 September 2007
YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiation5 September 2007
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process30 August 2007
Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients29 August 2007
XOMA Licenses Antibody Technology to Pfizer25 August 2007
Phase II study of IMC-1121B for advanced renal cell cancer opens for patient enrollment25 August 2007
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer22 August 2007
Protox acquires research program from Medicenna21 August 2007
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human PrimatesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports